Approach on the Use of Statins in a Sample of Doctors from Argentina. The COFEMA Study

pp 534-540

Authors

  • Andrés Rosende MTSAC Full member of the Argentine Society of Cardiology-Argentine Society of Cardiology-Hospital El Cruce “Dr. Néstor Kirchner”
  • Cristian Caniggia MTSAC Full member of the Argentine Society of Cardiology-Argentine Society of Cardiology-Investigaciones Médicas
  • Jorge Casuscelli To apply as Full Member of the Argentine Society of Cardiology-Argentine Society of Cardiology-Fundación Favaloro
  • Micaela Mirada Argentine Society of Cardiology- Fundación Favaloro
  • Daniel Comtesse Sociedad Argentina de Medicina
  • Adrián Charask Argentine Society of Cardiology-Clínica Bazterrica
  • Heraldo D’Imperio Hospital El Cruce “Dr. Néstor Kirchner”
  • Luis Cámera Sociedad Argentina de Medicina
  • Pascual Valdez Hospital El Cruce “Dr. Néstor Kirchner”
  • Carlos Tajer MTSAC Full member of the Argentine Society of Cardiology-Argentine Society of Cardiology-Hospital El Cruce “Dr. Néstor Kirchner”

DOI:

https://doi.org/10.7775/rac.es.v84.i6.8516

Keywords:

Hydroxymethylglutaryl, CoA Reductase Inhibitors, Cardiovascular Disease, Behavior, Lipids, Ezetimibe

Abstract

Background: Available information on the use of statins is very abundant and complex, and in recent years, different recommendations have been published in local and international guidelines. Since the evidence with statins has generated variations in their indication, it is interesting to know the degree of guideline acceptance and the approach of our medical community regarding their use.
Objective: The aim of this study was to identify physician approach on the use of statins in Argentina.
Methods: A 16-item survey was carried out to investigate the degree of agreement with different statin indications and usual dosage.A descriptive analysis was performed and comparisons by specialty and age group were carried out.
Results: The median age of the 598 respondents was 48 years. Most physicians agreed to indicate high doses of statins in secondary prevention and in diabetic patients. When LDL-C >190 mg/dL was the only risk criterion, 50% of respondents did not approve the indication. In primary prevention, one in three physicians agreed to discontinue treatment after normalizing cholesterol levels. In
two controversial conditions, such as chronic coronary artery disease in patients on dialysis and advanced coronary heart failure,the indication of statins was high. Most respondents monitor adverse effects with hepatograms and CPK measurements in asymptomatic patients.
Conclusions: The survey reflects the opinion of participating physicians on the indication of statins in different scenarios, revealing a partial acceptance of guideline recommendations. Accurate indications, statin doses and the addition of other therapies such as ezetimibe continue to generate different proposals and must be re elaborated and debated in order to optimize them.

Published

2025-09-02

Issue

Section

ORIGINAL ARTICLES

Most read articles by the same author(s)

1 2 3 4 5 6 > >>